Semax: Mechanistic Overview
internal_protocol · clinical · status: needs_provider_review
Metadata
Author: Axiom Knowledge Base
Citation: Internal reference summary compiled for the Axiom knowledge base (2026).
Embedding: pending
File: signed link
Summary (generated — provider review required)
Semax is a synthetic ACTH(4-10) analog, approved and used in Russia for stroke and cognitive indications; Western evidence is limited. Mechanism: modulates BDNF and other neurotrophic signaling, with reported neuroprotective and nootropic effects. Relevance: neurocognitive and neuroinflammatory presentations (e.g., brain fog).
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (4) · phenotypes (0)
evidence_reference, mechanism, safety_reference, dosing_reference
Evidence claims (4) · review items (3)
regulatory · pending
Semax is a synthetic ACTH(4-10) analog, approved and used in Russia for stroke and cognitive indications; Western evidence is limited.
mechanism · pending
Mechanism: modulates BDNF and other neurotrophic signaling, with reported neuroprotective and nootropic effects.
safety · pending
Safety: intranasal use; regulatory status outside Russia is investigational.
dosing · pending
Mechanistic background for provider review only — not a treatment recommendation or dosing guidance.
Extracted chunks (1)
64 approx tokens across 1 chunks.